ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
In vitro anticancer effect of epigallocatechin gallate nano-emulsion on head and neck cancers.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the anticancer potential of epigallocatechin gallate-loaded sodium alginate nanoparticles: impact of size variation on head and neck cancer cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Head and neck cancer, as one of the most common cancers, causes the death of many people worldwide every year. The current approaches to treat this cancer have not been successful, and recurrence, drug-resistance development, side effects, and high treatment costs are important problems necessitating the need for more effective drugs and treatment approaches. Epigallocatechin gallate (EGCG) is the most plentiful and biological-active catechin in green tea with proved anticancer effect. However, the stability, low bioavailability, and short half-life, limits its clinical use. Nanocarrier development may overcome these deficiencies by improving pharmacokinetics and pharmacodynamics. Therefore, this study aimed to examine the nano-emulsion containing EGCG for their anticancer activity. First, EGCG nano-emulsion was prepared, which was then characterized by dynamic light scattering (DLS), zeta potential, and Fourier transform infrared spectroscopy (FTIR). The toxicity of the nano-emulsion on the TSCC-1 cancer cell line was assessed by MTT and LDH assays. Cell migration rate, colony-formation ability, the apoptosis rate, and the expression level of BAX, BCL2, and VEGF genes after treatment of cancer cells were assessed. Moreover, the effect of EGCG nano-emulsion on the spheroid growth of TSCC-1 cells in three-dimensional (3D) culture was investigated. The FTIR results demonstrated the presence of EGCG in the nano-emulsion. The size and zeta potential of the nano-emulsion with and without EGCG were 17.53 ± 1.62 nm and - 0.166 ± 0.169 mV, and 14.0 ± 2.3 nm and - 0.266 ± 0.169 mV, respectively. The sustained drug release was observed. Moreover, the MTT assay exhibited that the cytotoxicity of the nano-emulsion was significant at a concentration of 80 µg/mL on TSCC-1 cells. The colony-formation assay revealed no colonies in the groups treated with nano-emulsion containing EGCG compared to the control group. The scratch test also showed the ability of nano-emulsion to inhibit cell migration. Furthermore, the induction of delayed apoptosis by 88.3 ± 3.18% was observed in the group treated with EGCG nano-emulsion at a concentration of 80 µg/mL. The expression of BCL2 and VEGF genes significantly decreased, while that of BAX gene increased. Moreover, the 3D culture showed a decrease in the size and growth of spheroids in the EGCG nano-emulsion-treated group compared to the control group. The results showed that the nano-emulsion containing EGCG has significant anticancer activity (TSCC-1) and may be a suitable treatment option for the management of squamous cell carcinoma of the head and neck.
Indexed as
Identifiers
40220124What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.